A multicenter randomized trial of personalized acupuncture, fixed acupuncture, letrozole and placebo on live birth for infertility in women with polycystic ovary syndrome

CURRENT STATUS: UNDER REVIEW

Shiya Huang
The First Affiliated Hospital of Guangzhou Medical University
ORCiD: 0000-0001-8677-5023

Min Hu
The First Affiliated Hospital of Guangzhou Medical University

Ernest Hung Yu Ng
University of Hong Kong

Elisabet Stener-Victorin
Karolinska Institutet

Yanhua Zheng
The Second Affiliated Hospital of Guangzhou Medical University

Qidan Wen
The First Affiliated Hospital of Guangzhou Medical University

Cong Wang
Guangdong Provincial Hospital of Traditional Chinese Medicine

Maohua Lai
The First Affiliated Hospital of Guangzhou Medical University

Juan Li
The First Affiliated Hospital of Guangzhou Medical University

Xingcheng Gao
the First Affiliated Hospital of Guangzhou Medical University
Xinhua Wang  
Guangzhou Medical University

Zhenxing Hu New  
Xuzhou Maternity and Child Health Care Hospital

Tian Xia New  
the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

Rongkui Hu New  
Affiliated Hospital of Nanjing University of Chinese Medicine

Jianping Liu New  
Beijing University of Chinese Medicine

Xiaohui Wen  
The First Affiliated Hospital of Guangzhou Medical University

Shuna Li  
The First Affiliated Hospital of Guangzhou Medical University

Kewei Quan  
Dongguan Hospital of Traditional Chinese Medicine

Xingyan Liang New  
the First Affiliated Hospital of Guangzhou Medical University

Hongcai Shang  
Dongzhimen Hospital, Beijing University of Chinese Medicine

Hongxia Ma  
doctorhongxia@126.com
Corresponding Author
ORCiD: 0000-0002-4477-613X

Jie Qiao  
Peking University Third Hospital

DOI: 10.21203/rs.2.14021/v2

SUBJECT AREAS  Integrative & Complementary Medicine

KEYWORDS
Acupuncture, Polycystic ovary syndrome, Personalized protocol, Fixed protocol, Letrozole
Abstract

BACKGROUND traditional Chinese Medicine (TCM) usually involves syndrome and disease differentiation, and for acupuncture selection of appropriate points and skillful needling techniques. Many clinical trials on acupuncture used fixed acupuncture protocols without accounting for individual differences. We here design a multicenter randomized controlled trial (RCT) to evaluate whether personalized or fixed acupuncture increases the likelihood of live births for infertility in women with polycystic ovary syndrome (PCOS) compared with letrozole or placebo letrozole. We hypothesis that letrozole is more effective than personalized acupuncture, and personalized acupuncture is more effective than fixed acupuncture, which is more effective than placebo letrozole. Moreover, personalized acupuncture is more likely to reduce miscarriage rate and the risk of pregnancy complications than letrozole.

METHODS / DESIGN The study is a randomized assessor-blind controlled trial. A total of 1,100 infertile women with PCOS will be recruited from 28 hospitals and randomly allocated into four groups: A) personalized acupuncture, B) fixed acupuncture, C) letrozole, or D) placebo letrozole. They will receive treatment for 16 weeks and the primary outcome is live birth. Secondary outcomes include ovulation rate, conception rate, pregnancy rate, pregnancy loss rate, changes in hormonal and metabolic parameters, and changes in quality-of-life scores. The adverse events (AEs) will be recorded throughout the trial. All statistical analyses will be performed using the SPSS program V.21.0 (SPSS, Chicago, Illinois, USA) and a p value <0.05 will be considered statistically significant.

DISCUSSION This study is the first multicentre RCT to compare personalized or fixed acupuncture, letrozole or placebo letrozole on live birth for infertility in women with PCOS. The findings will inform
whether personalized acupuncture therapy could be as an alternative treatment method on live birth for infertile women with PCOS.

Background

Polycystic ovary syndrome (PCOS) is associated with anovulation, infertility and pregnancy complications such as pregnancy-induced hypertension, pre-eclampsia, gestational diabetes and premature delivery[1,2]. The managements of anovulatory infertility in women with PCOS involve lifestyle modifications, pharmacological treatment (letrozole, clomid, metformin and gonadotropins), laparoscopic ovarian diathermy and in vitro fertilization[3]. Letrozole, an aromatase inhibitor, is the first-line therapy for infertility in women with PCOS[4]. However, letrozole has no improvement in pregnancy complications for the infertile women with PCOS. It is necessary to find an approach to improve both live birth rate and pregnancy complications.

Acupuncture has been used in China for more than 3000 years and is a core part of traditional Chinese medicine (TCM). Jedel et al[5] reported that acupuncture with manual and low-frequency electrical stimulation was superior to exercise and no treatment for improving menstrual frequency and reducing total testosterone levels. Johansson et al[6] demonstrated that repeated acupuncture resulted in higher ovulation frequency during the treatment period in women with PCOS. Besides, acupuncture can restore dysfunctional glucose homeostasis as well as adipose tissue gene expression and DNA methylation, in part via activation of autonomic nervous system in PCOS patients[7]. Nevertheless, a recent large multicenter trial in China demonstrated that acupuncture given in a fixed protocol did not improve the
live birth in women with PCOS when compared with placebo acupuncture or clomiphene citrate\textsuperscript{[8]}. Pastore et al claimed that placebo acupuncture have a similar improvement with fixed acupuncture in LH/FSH ratio for women in PCOS\textsuperscript{[9]}. Due to no research using placebo or no intervention as a comparator to determine the effect of acupuncture on live birth rate, the evidence of acupuncture treatment for infertile women with PCOS is still insufficient.

Acupuncture is a complex treatment and tailors to individual patients in TCM. According to TCM should signs and symptoms of each patient be considered in differential symptom diagnosis before selecting the acupoints. While, several studies had concluded that acupuncture was effective for some disease conditions\textsuperscript{[10,11]}, other did not find any differences between personalized, fixed and sham acupuncture on systolic or diastolic blood pressure\textsuperscript{[12]}. The recent study demonstrating no improvement of live birth rate\textsuperscript{[8]}, used a fixed and followed Western Medical acupuncture theories. Acupuncture points were selected according to innervation of ovaries and uterus and differs from the TCM theory with syndrome differentiation and treatment. Thus, it is not certain if acupuncture is more effective than no intervention for ovulation induction and live birth rate.

Though there was no study showing the efficacy of acupuncture in pregnancy complications, the advantage of acupuncture in losing weight\textsuperscript{[13]}, reducing total testosterone levels\textsuperscript{[5]} and improving insulin resistance\textsuperscript{[14]} may provide potential benefits in reducing pregnancy complications such as miscarriage, gestational diabetes and gestational hypertension etc.

In most studies on acupuncture, fixed acupuncture was used while some\textsuperscript{[10,11,15-17]} demonstrated efficacy of personalized acupuncture, which was provided based on
the disease differentiation and the TCM theory. There is no such study in the management of anovulatory infertility in women with PCOS. Therefore, we aim to investigate the efficacy of personalized acupuncture based on the TCM theory, fixed acupuncture, letrozole and placebo letrozole on the live birth rate of infertility in women with PCOS.

Objectives

The objectives of the present trial are to test the following four hypotheses for infertility in women with PCOS:

1. Letrozole is more likely to induce ovulation and results in live birth than personalized acupuncture.
2. Personalized acupuncture is more likely to induce ovulation and results in live birth than fixed
3. Fixed acupuncture is more likely to induce ovulation and results in live birth than placebo letrozole.
4. Personalized acupuncture is more likely to reduce miscarriage rate and the risk of pregnancy complications compared with letrozole, fixed acupuncture and placebo letrozole.

Methods and design

Study design

This is a multi-center randomized trial involving four treatment groups. The research protocol is compliant with the Consolidated Standards of Reporting Trials (CONSORT)\textsuperscript{[18]} guidelines and Standards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA)\textsuperscript{[19]}, as well as with the Standard Protocol with the
Recruitment

A total of 1,100 infertile women with PCOS will be recruited from 28 hospitals in China. They will be randomly allocated into four groups: personalized acupuncture, fixed acupuncture, letrozole or placebo letrozole. Women will be recruited through advertisements in local newspapers and bulletin boards in each trial center. Eligible women will be approached and sign the consent form after detailed explanation of the study design and comprehensive counseling.

Inclusion criteria are:

1. Age of women between 20 and 40 years.
2. Chronic oligomenorrhea or amenorrhea: oligomenorrhea is defined as an intermenstrual interval > 35 days or < 8 menstrual bleedings in the past year. Amenorrhea is defined as an intermenstrual interval >90 days.
3. Hyperandrogenism (either hirsutism or hyperandrogenemia) or polycystic ovaries on ultrasound. Hirsutism is determined by a modified Ferriman-Gallwey (FG) Score ≥ 5 at screening examination[21], and biochemical hyperandrogenism is defined as total testosterone (T) >2.6 nmol/L and free testosterone ≥ 6.0 pg/mL (the cutoff level may differ from each study site)[22]. Polycystic ovaries are present when the number of small antral follicles (2–9 mm in diameter) ≥12 or ovarian volume > 10mL on transvaginal scanning[23].
4. At least one patent tube shown by hysterosalpingogram or diagnostic
laparoscopy within 3 years if the patient does not have a history of abortion or pelvic operation. If the patient has a history of pregnancy and no history of pelvic operation within the past 5 years, she is not required to undergo a tubal patency test.

5. Sperm concentration $\geq 15 \times 10^6$/mL and total motility $\geq 40\%$ or total motile sperm count $\geq 9$ million in the semen analysis of the husband $^{[24]}$.

6. The couple agree to have regular intercourse i.e. 2-3 times per week during the study period.

Exclusion criteria included:

1. Exclusion of other endocrine disorders
   a. patients with hyperprolactinemia (defined as two prolactin (PRL) levels at least one week apart $\geq 25$ ng/mL)
   b. Patients with FSH levels $> 15$ mIU/mL. A normal level within the last year is adequate for entry
   c. Patients with uncorrected thyroid disease (defined as thyroid-stimulating hormone (TSH) $< 0.2$ mIU/mL or $> 5.5$ mIU/mL). A normal level within the last year is adequate for entry
   d. Patients diagnosed with Type I or Type II diabetes who are poorly controlled (defined as glycated haemoglobin (HbA1c) level $> 7.0\%$), or patients receiving antidiabetic medications such as metformin, insulin, thiazolidinediones, acarbose, or sulfonylureas
   e. Patients with suspected Cushing's syndrome.

2. Use of other TCM treatments including Chinese herbal prescriptions and acupuncture in the past 3 months.
3. Use of other western medications known to affect reproductive function or metabolism in the past 2 months.

4. Pregnancy within the past 6 weeks.

5. Within 6 weeks postabortion or postpartum.

6. Breastfeeding within the last 6 months.

7. Not willing to give written consent to the study.

8. Additional exclusion criteria are as follows.
   a. Patients taking other medications known to affect reproductive function or metabolism. These medications include oral contraceptives, depot progestins, hormonal implants (including Implanon), GnRH agonists and antagonists, antiandrogens, gonadotropins, antiobesity drugs, antidiabetic drugs such as metformin and thiazolidinediones, somatostatin, diazoxide, angiotensin-converting-enzyme inhibitors, and calcium channel blockers. The washout period on these medications will be two months, longer washouts may be necessary for certain depot contraceptive forms or implants, especially where the implants are still in place. A one-month washout will be required for patients on depot progestins.
   
   b. Patients with liver disease defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2 times normal or total bilirubin > 2.5 mg/dL. Patients with renal disease defined as blood urea nitrogen (BUN) > 30 mg/dL or serum creatinine > 1.4 mg/dL.
   
   c. Patients with hemoglobin < 10 g/dL.
   
   d. Patients with a history of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident.
   
   e. Patients with known heart disease that is likely to be exacerbated by
pregnancy.
f. Patients with a history of suspected cervical carcinoma, endometrial carcinoma, or breast carcinoma. A normal Pap smear result will be required for women 21 years and over.
g. Patients with a current history of alcohol abuse. Alcohol abuse is defined as >14 drinks/week or binge drinking.
h. Patients enrolled into other investigative studies that require medications, prescribe the study medications, limit intercourse, or otherwise prevent compliance with the protocol.
i. Patients who anticipate taking longer than a one-month break during the protocol should not be enrolled.
j. Patients with a suspected adrenal or ovarian tumor secreting androgens.
k. Couples with previous sterilization procedures (vasectomy, tubal ligation), which have been reversed. The prior procedure may affect study outcomes, and patients with both a reversed sterilization procedure and PCOS are rare enough that exclusion should not adversely affect recruitment.
l. Subjects who have undergone a bariatric surgery procedure in the recent past (<12 months) and are in a period of acute weight loss or have been advised against pregnancy by their bariatric surgeon.
m. Patients with untreated poorly controlled hypertension defined as a systolic blood pressure 160 mmHg or a diastolic 100 mm Hg obtained on two measures obtained at least 60 minutes apart.
n. Patients with known congenital adrenal hyperplasia.7

**Intervention**
All participants will be informed of benefits of regular physical exercise and will be instructed to have regular intercourse every 2 to 3 days.

Women in both personalized and fixed acupuncture groups will receive acupuncture treatment three times a week with a maximum of 48 treatment sessions over 16 weeks. Acupuncture treatment will start on day 3 after a spontaneous period or after a withdrawal bleeding following progestin. They will be contacted by phone if they miss the scheduled appointment. If they miss appointments during treatment, missed appointments will be clearly documented in the record for analysis later. They will be treated for up to 16 weeks. If they become pregnant, the acupuncture treatment will be stopped. For personalized and fixed acupuncture group, credibility and expectancy questionnaires will be completed on the third acupuncture treatment and the last acupuncture treatment.

**Personalized acupuncture protocol**

The rationale of personalized acupuncture protocol is based on Zang-fu organ system, Yin-yang theory and clinical rules for PCOS acupoint selection\(^{[25]}\). Two sets of acupoints will be selected for the two types (Table 1). The basic acupoint-prescription includes the conception vessel (CV) 4, CV 6, CV 12 and spleen (SP) 6 bilaterally, stomach (ST) 25 bilaterally, extra point of chest and abdomen (EX-CA) 1 bilaterally, ST 40 bilaterally and SP 9 bilaterally. Additional point ST 36 bilaterally and moxibustion as adjuvant therapy will be added for the type of yang deficiency of spleen and kidney, while additional points kidney (K) 13, liver (LR) 3 for the type of yin deficiency of liver and kidney. Besides, flexible modifications of 2-3 acupoints will be performed according to patients’ special symptoms.

The additional points ST 36, K 13, LR 3 and all the basic points will be inserted with
disposable needles (Huanqiu, Suzhou Acupuncture Goods Co., Suzhou, China. Size: 0.30×25mm and 0.30×40mm). The depth and degree of puncture for each acupoint is described in Table 1, which could be adjusted according to body shape of participants as shallower for thin women and deeper for fat women. The needles for abdominal acupoints should be inserted until resistance without manual stimulation. After inserting the needles, the acupuncturist will rotate the needles to evoke needle sensation (de qi). De-qi (a dull aching and irradiating sensation indicative of effective needle placement) refers to a sensation of numbness, distension, or electrical tingling at the needling site that might radiate along the corresponding meridian. Once de-qi is achieved, further techniques might be utilized which aim to "influence" the de-qi. Simultaneously, the other techniques of acupuncture with thumb and forefinger to tonify or sedate qi. Tonifying is used to reinforce deficiency while sedating is to clear excess, which are the two manners to stimulate qi in the acupuncture in China. The former is the needles rotate slower and gentle in clockwise direction. Conversely, the latter is turning faster and more forcefully in counterclockwise rotation. Furthermore, the points SP 6 to SP 9 bilaterally for both types will be connected to electrical stimulator (SDZ-IIB, Huatuo, China) and stimulated with low-frequency at 2 Hz, continuous wave and the intensity is adjusted to produce local muscle contractions without pain or discomfort.

Abdominal and back moxibustion will be used for the type of yang deficiency of spleen and kidney (Figure 1). Ignited 1.5 moxa sticks (Hanyi, Nanyang, China; Size: 18mm×200mm) in a special moxa box (19.5×29.5×16.5cm) will be used for a treatment session. The moxa box will be placed onto patients’ abdomen with acupuncture treatment simultaneously for 30 minutes. The box of abdominal moxibustion will cover from the midpoint of sternal body xiphoid junction and
umbilicus to superior margin of pubic symphysis. After 30 minutes, the moxa box on the back will be continued for another 30 minutes subsequently without acupuncture. And the box will cover from 11th thoracic vertebra to the 4th sacral posterior foramen. Moxibustion will be stopped at any time if the participants feel mouth parched, canker sore and sore throats. Women without moxibustion will be provided local radiation for abdomen by special electromagnetic spectrum therapy apparatus. Needles not connected to the electrical stimulator or not given moxibustion will be manually stimulated to evoke de-qi every 10 minutes, in total four times.

Fixed acupuncture protocol

The fixed acupuncture protocol is based on the previous study[8]. Two sets of acupuncture points will be alternated every second treatment (Table 2). The first set consists of CV 3, CV 6, ST 29 bilaterally, SP 6 bilaterally, SP 9 bilaterally, governor vessel (GV) 20 and large intestine (LI) 4 bilaterally. In total, 11 needles will be placed. The needles for abdominal acupoints should be inserted until resistance without manual stimulation. Other needles will be manipulated manually by rotation to evoke needle sensation, de qi. CV 3, CV 6 (mid-line), ST 29 bilaterally, SP 6 bilaterally and SP 9 bilaterally will be connected to an electrical stimulator (SDZ-IIB, Huatuo, China). The second set consists of 13 needles: ST 25 bilaterally, ST 29 bilaterally, CV 3, CV 6, SP 6 bilaterally, LR 3 bilaterally, pericardium meridian (PC) 6 bilaterally and GV 20. The following points will be connected to an electrical stimulator: ST 25 bilaterally, ST 29 bilaterally, SP 6 bilaterally, LR 3 bilaterally.

Electrical stimulation is given with low-frequency electric acupuncture (EA) of 2Hz, continuous wave, with an intensity adjusted to produce local muscle contractions without pain or discomfort. Electromagnetic spectrum therapy apparatus will be
used during the treatment. Needles not connected to the electrical stimulator and not for abdominal acupoints will be manually stimulated to evoke de-qi every 10 minutes, in total four times.

**Letrozole**

Women in the letrozole group will receive letrozole without acupuncture. Letrozole (Femara, Novartis Pharmaceuticals, Basel, Switzerland) 2.5 mg (1 pill) will be given daily from day 3 to day 7 of the spontaneous menstrual cycle or after a withdrawal bleeding following progestin. If there is response with ovulation (ie, the serum progesterone level on day 21 or day 28 of the cycle is higher than 3 ng/mL) this dose will be maintained. In those with no ovulatory response, letrozole tablets of the next ovulation cycle will be taken on the day 28 of the menstrual cycle and the letrozole dose will be increased to 5 mg (2 pills) a day for 5 days. If there is still no response, the dose will be increased to 7.5 mg (3 pills) per day for 5 days in the next cycle. The maximum daily dose of letrozole will be 7.5 mg daily for five days.

**Placebo letrozole**

Women will receive placebo letrozole with no acupuncture. Placebo letrozole will have the same appearance as letrozole (Dongyangguang pharmaceutical Co. LTD, Guangdong, China). Placebo letrozole will be given in the same way as letrozole, women will receive 1 tablet a day of placebo letrozole from the day 3 to day 7 of the menstrual cycle and placebo letrozole dose will be increased 2 tablets a day in the next cycle if there is no response. The maximum daily dose of placebo letrozole will be 3 tablets daily for five days.
Randomization and patient allocation

An online computerized program of web-based Research Management (ResMan) database system will be used to allocate patients in 1: 1: 1: 1 ratio. The data coordinating center (DCC) statisticians generated and validated the randomization scheme for the study before it was implemented in ResMan database system. When a participant is enrolled, an investigator of participating site will take out sealed envelope and enter the ID number into the ResMan database system, and login a password protected secured website designed by the DCC to find the group allocation.

Blinding

The acupuncture groups will be known only to the acupuncturists besides the ResMan data manager. The letrozole and the placebo letrozole having the same appearance will be organized in a kit consisting of one cycle tablets for each subject and one subject will at most take 45 tablets in total for 4 cycles. The sealed envelope with 4 cycles tablets will be labeled with an ID number mapped to the letrozole or placebo letrozole known only to the ResMan personnel. Participants and investigators will be blinded to the letrozole or placebo letrozole allocation. All outcome assessors and the statisticians performing data analysis will be blinded to group allocation. Except for emergencies, unblinding of individual study subjects will not take place until all subjects have delivered and reported outcomes to the DCC. In the event that emergency unblinding is needed, only site PI will be able to unblind the participant to treatment by connecting the director of DCC. The site PI and DCC staff will receive notification from the central randomization service when emergency unblinding has occurred.
**Study-specific visits and procedures** (Figure 2)

Women will attend up to five visits, including the screening visit, baseline visit, treatment visit, pregnancy visit and end of treatment visit (Table 3). Adverse events (AEs) and concomitant medications will be recorded during every visit. Face-to-face adherence reminder sessions will take place at each study visit thereafter.

**Screening visit**

Women are screened in the morning after an overnight 12-h fast. Detailed information about the study design is given.

**Physical examination**

Complete physical examinations will be performed including height, weight, hip, waist measurements, and vital signs. Height and weight will be recorded to the nearest 0.1 cm and 0.1 kg respectively. Waist and hip circumference will be recorded to the nearest 1 cm. Hirsutism assessment by FG, acne by standard acne lesion counts.

**Transvaginal ultrasound of ovaries**

Ovaries, including the ovarian size in three dimensions, the size of the largest ovarian follicle/cyst and size of every follicle with a mean diameter greater than 10 mm, and total antral follicle count (small follicles with mean diameter of 2-9 mm) of each ovary will be obtained through transvaginal ultrasound.

**Pregnancy test**
A urine and serum pregnancy test will be performed to exclude pregnancy.

**Laboratory tests**

Blood samples will be collected for the following laboratory: T, sex hormone binding Globulin (SHBG), FSH, luteinising hormone (LH), progesterone (P), estradiol (E2), PRL, fasting glucose, fasting insulin, HbA1C, C-peptide, and lipid profile (cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C)). PCOS safety screen: liver profile (ALT, AST, total bilirubin), renal profile (BUN and creatinine), thyroid profile (TSH, T3, free T4), complete blood cell count (CBC), cervical Pap smear or TCT. Every woman should have T and SHBG assay in local labs. Free androgen index will be calculated.

**Pre-conception counseling**

TORCH screening (Toxoplasma, Rubella Virus, Cytomegalo Virus, Herpes Virus), HIV screening and folic acid prescription will be included.

**Progestin withdrawal**

Women without evidence of ovulation on baseline screening will be provided progestin to induce withdrawal bleeding, with instructions to begin medication once eligibility has been determined. They will sign the consent form after comprehensive counseling.

**Baseline visit**

The baseline visit will be around day 2–5 of a spontaneous period or after a withdrawal bleeding if a woman fulfills the selection criteria and has signed the
consent form. Fasting blood samples will be obtained from the patients and will be shipped to the core laboratory for analysis and stored for a minimum of 5 years, and perhaps further use in the future, which is stated in informed consent (supplementary file 2). Moreover, urine or serum pregnancy test will be done at this visit.

**Questionnaires**

Women will fill in the following questionnaires: the short form 36 (SF 36) of health-related quality of life (QOL), the Polycystic Ovary Syndrome Questionnaire (PCOS-QOL), the Chinese Quality of life (ChQOL), Zung Self-Rating Anxiety Scale (SAS) and Zung Self-reported Depression Scale (SDS).

TCM differentiation of syndromes of PCOS is mainly for the deficiency of liver-kidney-yin type, and the deficiency of spleen-kidney-yang type. The TCM syndrome diagnosis will be made by principal investigator and acupuncturist in each participating site according to a standard questionnaire during baseline visit and end of treatment visit. If the diagnosis is differ from each other, they will discuss until reaching an agreement. Syndrome differentiation in TCM is the comprehensive analysis of clinical information gained by the four-main diagnostic TCM procedures: observation, listening, questioning, and pulse analysis.

All baseline measures will be repeated in all subjects at the end of treatment visit.

**Treatment visit**

The women will be instructed to have intercourse once every 2 or 3 days. A serum progesterone level test will be performed in local laboratory on day 21 of the cycle. An elevated level of progesterone >3 ng/mL is considered to indicate evidence of
ovulation. If there is no ovulation, serum progesterone level will be checked every week until ovulation. If ovulation, serum pregnancy test will be performed after a week. Women should make a urine pregnancy test at any time if they are suspected to be pregnant.

We will determine whether the women have anovulation response based on the serum progesterone level. There will be three possible scenarios: ovulation, delayed ovulation and no ovulation (1) Ovulation: serum progesterone level on day 21 of the cycle >3 ng/mL. A serum pregnancy test will be performed after a week to exclude pregnancy, letrozole or placebo letrozole will be started on day 3 of the period, and the letrozole or placebo letrozole dose will be maintained. (2) Delayed ovulation: serum progesterone level in the third week <3 ng/mL. In this case, we will wait for one more week, and check serum progesterone level again. A serum pregnancy test will be performed after a week if ovulation to exclude pregnancy. Letrozole or placebo letrozole will be started on day 3 of the period, and the letrozole or placebo letrozole dose will be maintained. (3) No ovulation: It will be defined as negative serum progesterone levels on day 21 and day 28. In the letrozole and placebo letrozole groups, women will take letrozole or placebo letrozole on day 28 of the period and one more tablet per day will be given for 5 days until the maximum daily dose of 3 tablets a day. Day 28 will be defined as day 1 of next cycle, and serum progesterone test will be done every week until ovulation.

Every period will be recorded, including the date, amount and duration of menstruation.

End of treatment visit

End of treatment visit will be performed when women conceive or finish four cycle
treatments. Baseline measures will be repeated in all subjects including vital signs, height, weight, hip and waist measurements, hirsutism and acne assessments, sex hormone steroids (FSH, LH, T for women not pregnant, and HCG, P, E2, T for pregnant women), SHBG, metabolic profile (glucose and insulin concentrations, HbA1C, C-peptide, cholesterol, triglycerides, HDL-C, LDL-C), and safety profile (AST, ALT, total bilirubin, BUN, creatinine). Subjects will return menstrual and intercourse journal logs, and their AEs and concomitant medications will be recorded. Fasting blood samples will be obtained, and TCM syndrome diagnosis and questionnaires SF36, PCOS-QOL, ChQOL, SAS and SDS will be repeated.

**Pregnancy visit (only with conception)**

Serum progesterone and hCG levels will be determined at local sites to document ovulation and pregnancy. Serial serum hCG level will be checked on a weekly basis if pregnant. Serum beta hCG > 10 IU/L indicates pregnancy. Pelvic ultrasound will be arranged to determine the location, number and viability of the pregnancy when serum hCG is 2000-4000 IU/L.

Women who conceive will be followed till around 9 weeks gestational age and will be referred to their prior or referring doctors for antenatal care. Subsequent scans will be performed at week 18–24, 32, and 36 or at the prescription of the obstetrician. In the present trial, pregnant women who present with threatened miscarriage or are considered to have a significant risk for miscarriage can be given oral Duphaston (10 mg three times a day, Solvay Pharmaceuticals B.V.) till 12 weeks of gestation or 1 week after the vaginal bleeding stops. This information will be documented in the record form. No other medications including hCG, herbal medications, and acupuncture will be given.
Follow-up of pregnancies

For those women who have an ongoing pregnancy, arrangements will be made to follow the outcome of the pregnancy at the end of the first trimester and also after delivery or termination of gestation. All pregnancies (including multiples) will be followed to monitor weight, glucose tolerance, blood pressure and fetal growth and to determine the pregnancy outcomes. The glucose tolerance will be measured by oral glucose tolerance test in all pregnancies at 24–28 weeks of pregnancy. Women will be instructed to inform the study personnel of the outcomes of the pregnancy, and we will obtain delivery record from the obstetricians to determine the birth weight, length of gestation, and any prenatal complications of the mother or neonatal complications of the infant. Phone contacts will be initiated if the pregnant woman has not contacted the study personnel within 6 weeks of the original estimated date of childbirth.

We will collect pregnancy outcome data and track the outcomes of all women who have a positive serum pregnancy screen during the course of this study. We will record biochemical pregnancies (defined as positive serum pregnancy screens without ultrasonically detected pregnancies), ectopic pregnancies and all intrauterine pregnancy losses both before and after 20 weeks, including miscarriages, abortions, fetal deaths and stillbirths.

Outcomes

Primary outcome

The primary outcome is the live birth rate, defined as delivery of any viable infant after 28 weeks of gestation.
Secondary outcomes

The secondary outcomes include ovulation rate, conception rate, pregnancy rate, pregnancy loss rate, changes in hormonal/metabolic parameters, changes in quality-of-life scores, and changes in AEs.

Ovulation rate The ovulation rate per participant and per cycle will be analyzed. It will be defined as ovulation when the serum progesterone level on day 21 or day 28 of the cycle is higher than 3 ng/mL. The ovulation rate per participant will be calculated as the proportion of women who has ovulated at least once during the treatments among the total women in the primary analysis. The ovulation rate per cycle will be calculated as the proportion of cycles in which ovulation occurs among all tested cycles in the primary analysis.

Conception rate Conception will be defined as positive serum hCG. Thus, the cumulative conception rate was the proportion of women who conceived during the four treatment cycles among all women in the primary analysis.

Pregnancy rate Pregnancy defined as an intrauterine pregnancy with fetal heart motion as determined by transvaginal ultrasound. The cumulative pregnancy rate was the proportion of pregnant women among total participants in the primary analysis.

Pregnancy loss rate Pregnancy loss was defined as pregnancy loss occurring from conception to 27 completed weeks of gestational age in this trial, including pregnancy loss in the first trimester, or in second or third trimester, biochemical pregnancy loss, and ectopic pregnancy. The pregnancy loss rate was the proportion of women who aborted among all participants who conceived.

Changes in hormonal/metabolic parameters Hormonal/metabolic profiles will be
performed at the baseline visit and end of treatment visit. Means of changes in hormonal/metabolic parameters before and after treatments will be in the primary analysis.

Changes in quality-of-life scores Quality-of-life scores will be assessed by questionnaires of SF 36, PCOS-QOL, ChQOL, Zung SAS and Zung SDS. The participants will finish the questionnaires at the baseline visit and repeat it at the end of the treatments. Higher scores of SF 36, PCOS-QOL, ChQOL questionnaires indicate better function, while higher scores of Zung SAS/SDS indicate worse anxiety/depression. Mean of changes in quality-of-life scores of each group will be analyzed.

Adverse events All AEs will be categorized and the percentage of patients experiencing AEs and serious adverse events (SAEs) during the treatment period and follow-up period will be documented and reported. For fetuses and newborns, SAEs and AEs will be reported as those occurring after 20 weeks of gestation through birth and those occurring within 28 days after birth, respectively. Moreover, SAEs will include fatal or immediately life-threatening, severely or permanently disabling, an event that required or prolonged hospitalization, overdose (intentional or accidental), congenital anomaly, pregnancy loss after 12 weeks’ gestation, neonatal death up to 6 weeks after delivery or any event so deemed as serious by the site PIs. DSMB will review AEs on a quarterly basis and review SAEs immediately.

Sample size calculations
The overall live birth proportion for women who received letrozole for six month was 36.3%[26], while for women who received fixed acupuncture twice a week with a
maximum of 32 acupuncture treatments was 13.9%[8]. Thus, we hypothesise that the live birth rate is 35% for letrozole treatments with four cycles and 15% for fixed acupuncture with three times a week. We chose 10% as the minimal clinically detectable difference that is likely to change clinical practice. Assuming a 35% live birth rate with letrozole, a 25% live birth rate with personalized acupuncture, a 15% live birth rate with fixed acupuncture and a 5% live birth rate with placebo letrozole. 80% power at a significance level of 0.05, we calculated that 250 subjects per treatment group were required. The sample size was increased from 250 to 275 per group considering a 10% dropout rate, 1100 women for four groups would be enrolled.

**Analysis of data**

The primary analysis will use an intent-to-treat approach to examine differences in the live birth rate among the four treatment groups. Primary efficacy analysis will be done by comparing the treatment groups with respect to the primary outcome of live birth using the Pearson chi-square test. For the secondary supportive analysis, we will fit a logistic regression model to compare the treatment arms with respect to the primary outcome of live birth, adjusting for other factors such as randomization stratification of study site and prior exposure to study medications. Comparisons of variables such as live birth rate, ovulation rate, conception rate, pregnancy rate, multiple pregnancy rate and miscarriage rate will include relative risk and 95% CIs in addition to the χ2 test. Changes in laboratory values were assessed by ANCOVA.

The analysis of other secondary (supplemental) outcomes measured over time will entail the application of statistical methods that have been developed for correlated
data since repeated observations will be made over time on each individual. For secondary outcomes such as hormone levels, a linear mixed-effect model will be fit where the main independent variables will be treatment group, time, and their interaction as well as the designed randomization stratification factors as covariates. Logistic regression models will be used in secondary analyses to evaluate the predictive value of treatment arm, clinical site, body mass index and other explanatory variables on binary outcomes (e.g., live birth, abortion). Cox proportional hazards models and a Kaplan-Meier method will be applied to compare time to pregnancy in the treatment groups. Effects on QoL were tested as the change from baseline of the Medical Outcomes Study Short Form physical and mental component scores by univariate and multivariate ANCOVA. Adequacy of blinding was tested by Fisher’s exact test comparing true assignments to participant guesses, including “don’t know.” In order to evaluate acupuncture as unique therapy, the combination of personalized acupuncture group and fixed acupuncture group will be also compared with letrozole/placebo letrozole group for the analysis of primary outcome. Differences in adverse event rates were analyzed in a negative-binomial generalized linear model. A P<0.05 with 2-tailed test is considered significant. All statistical analyses will be performed using the SPSS program V.21.0 (SPSS, Chicago, Illinois, USA).

**Imputation procedure for missing data**

We will report reasons for withdrawal for different randomisation groups and compare the reasons qualitatively. The effect that any missing data might have on the results will be assessed via sensitivity analysis of augmented data sets. Dropouts (essentially participants who withdraw consent for continued follow-up)
will be included in the analysis by modern imputation methods for missing data.

**Quality assurance**

To ensure that treatments are of a high standard and delivered in accordance with the trial protocol, all acupuncturists with TCM certificate and 1-year experience receive a study specific theoretical course and a study specific practical training, totally 3 times before the beginning of the study, 1–3 days per time, and 1 time, four hours after one month of the study beginning. They are graduate students in Chinese medicine and have received general acupuncture training during their studies. All acupuncturists have to pass the theory and practical tests.

**Study governance and management**

The study is led by a steering committee consisting of an independently-selected chair, site PIs and investigators. Each of these individuals has one vote. Decisions are reached by majority consensus and formal vote. The steering committee meets four times a year face to face and monthly via phone conferences or emails regularly. Additionally, there are subcommittees including a protocol committee, a recruitment committee, a publication committee.

There is an independent Data and Safety Monitoring Board (DSMB). DSMB holds regular conference calls to review the protocol with respect to ethical and safety standards, to monitor the safety of the trials, to monitor the integrity of the data with respect to the original study design, and to provide advice on study conduct. The DSMB also can make the premature closure of the study for a variety of reasons including poor recruitment, adverse effects of study medications, or a clear trend in one of the blinded treatment arms in live births exceeding our expectations.
Data access, management and quality control of data

Both the Case record form (CRF) and web-based electronic database will be used to manage individual participant data. Quality control of the data will be handled at three different levels: the investigators will be required to ensure the accuracy of the data as the first level of control when they input the records in CRF. The second level will include data monitoring and validation that will be carried out by an independent group. The third level will be the site visits, during which data in ResMan will be compared with the source documents. Identified errors will be resolved by ResMan and clinical sites.

A web-based electronic database, ResMan (www.medresman.org), is used as a double input database. The ResMan will oversee the intra-study data sharing process. All principal investigators will be given access to the cleaned data sets. Project data sets will be housed on the ResMan database system for the study, and all data sets will be password protected. The principal investigators will have direct access to their own site’s data sets as well as access to other sites’ data by request. To ensure confidentiality, data dispersed to project team members will be blinded to any identifying participant information.

Ethics and dissemination

All women and their husbands will be asked to sign a consent form prior to joining the study, and they will be made fully aware that they are free to withdraw from the study at any time. The results of this trial will be disseminated in peer-reviewed journals and presented at international meetings.
Discussion

To the best of our knowledge, no study has investigated whether personalized acupuncture has the potential to increase the live birth rate in women with PCOS. Our study is the first multicentre RCT to compare personalized or fixed acupuncture, letrozole or placebo letrozole on live birth for infertility in women with PCOS. The hypothesis is letrozole is more effective than personalized acupuncture, and personalized acupuncture is more effective than fixed acupuncture, which is more effective than placebo letrozole. Moreover, personalized acupuncture is more likely to reduce miscarriage rate and the risk of pregnancy complications than letrozole. Considering the treatment principle based on syndrome/pattern differentiation in TCM, kidney, liver and spleen are the top three zang-fu organs associating with the development of PCOS, and yin or yang deficiency is the essential cause while pathological products as phlegm is superficial\textsuperscript{[27]}. Therefore, the therapeutic proposal should be reinforcing liver-kidney-yin deficiency, promoting spleen-kidney-yang circulation and resolving phlegm. We will divide the individual group into two types as the theory of TCM, “liver-yin and kidney-yin deficiency” and “spleen-yang and kidney-yang deficiency”. This method is similar the actual clinical practice and can be used in future studies. The fixed acupuncture regimen is controversial based on the theory of TCM’s acupuncture.

Trial Status

This trial was approved on March 9, 2018. The recruitment began on August 13, 2018 and is expected to be completed by the August 13, 2021. The trial procedures are expected to be completed by the end of May, 2022 when considering ten month
pregnancies follow up until collecting the information of live birth. This is version 3.0 of the protocol, dated May 12, 2019.

Abbreviations

AEs: Adverse events; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BUN: Blood urea nitrogen; CBC: Complete blood cell count; ChQOL: Chinese Quality of life; CONSORT: Consolidated Standards of Reporting Trials; CRF: Case record form; CV: Conception vessel; DCC: Data coordinating center; DSMB: Data and Safety Monitoring Board; E2: Estradiol; EA: Electric acupuncture; EX-CA: Extra point of chest and abdomen; FG: Ferriman-Gallwey; FSH: Follicle-stimulating hormone; GV: Governor vessel; HbA1c: Glycated haemoglobin; HDL-C: High-density lipoprotein cholesterol; K: Kidney; LDL-C: Low-density lipoprotein cholesterol; LH: Luteinising hormone; LI: Large intestine; LR: Liver; P: Progesterone; PC: Pericardium meridian; PCOS: Polycystic ovary syndrome; PCOS-QOL: Polycystic Ovary Syndrome Questionnaire; PRL: Prolactin; QOL: Quality of life; RCT: Randomized controlled trial; ResMan: Research Management; SAEs: Serious adverse events; SAS: Self-Rating Anxiety Scale; SDS: Self-reported Depression Scale; SF 36: Short form 36; SHBG: Sex hormone binding Globulin; SP: Spleen; SPIRIT: Standard Protocol with the Standard Protocol Items: Recommendations for Interventional Trials; ST: Stomach; STRICTA: Standards for Reporting Interventions in Clinical Trials of Acupuncture; T: Total testosterone; TCM: Traditional Chinese Medicine; TSH: Thyroid-stimulating hormone.

Declarations

Ethics approval and consent to participate
Central ethical approval has been confirmed form the Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University (Reference approval no. 2018019) and we will not begin recruiting at other centres in the trial until local ethical approval has been obtained. Any protocol modifications will be approved by this ethics committee before its implementation. All participants and their husbands will sign the informed consent prior to participation, and they will be made fully aware that they are free to withdraw from the study at any time. All AEs and SAEs during the treatment period will be documented.

This study is referred as the Clinical trial of Personalized Acupuncture on PCOS (PPCOSAct). It has been registered at Clinicaltrials.gov (NCT03625531, URL: https://clinicaltrials.gov/ct2/show/NCT03625531) and Chinese Clinical Trials Registry (ChiCTR1800017304, URL: http://www.chictr.org.cn/showproj.aspx?proj=28407).

Consent for publication

Decisions concerning publications are determined by consensus (majority vote) of the collaborating PIs (or designate). All authorships for final publication are expected to meet criteria as set forth by International Committee of Medical Journal Editors. (Uniform requirements for manuscripts submitted to biomedical journals. http://www.icmje.org. Updated October 2008.)

Availability of data and materials

The supplementary data will be stored in a public internet website e.g. Dryad. Finally, the individual participant data except the private information will be allowed to be shared with the public.

Competing interests

The authors declare that they have no competing interests.

Funding source
This work was supported by the High-level University Construction Innovation Team Training Foundation in Guangzhou Medical University, and Guangdong Province High-level Hospital Construction Foundation.

Authors’ contributions

EHYN, ESV and HM conceived and designed the study. SH and MH drafted the manuscript for important intellectual content. HM sought funding and ethical approval. MH, JQ, EHYN and ESV critically revised the manuscript and designed the acupuncture protocol. XG and XW played an important role in securing the financial assistance. JL made some suggestions for the study design and analysis. SH, YZ, QW, CW, ML, JL ZH, TX, RH, XW, SL, KQ, XL, HS, HM and JQ recruited subjects and carried out acupuncture treatment. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Jie Qiao or Hongxia Ma.

Acknowledgements

Not applicable.

References

[1] Homburg R. Management of infertility and prevention of ovarian hyperstimulation in women with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004;18(5):773-88. doi: 10.1016/j.bpobgyn.2004.05.006

[2] Palomba S, de Wilde MA, Falbo A, et al. Pregnancy complications in women with polycystic ovary syndrome. Hum Reprod Update. 2015; 21 (5): 575-92. doi: 10.1093/humupd/dmv029

[3] Thessaloniki EA-SPCWG. Consensus on infertility treatment related to polycystic
ovary syndrome. *Hum Reprod* 2008;23(3):462-77. doi: 10.1093/humrep/dem426

[4] Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. *Hum Reprod* 2018;33(9):1602-18 doi: 10.1093/humrep/dey256

[5] Jedel E, Labrie F, Oden A, et al. Impact of electro-acupuncture and physical exercise on hyperandrogenism and oligo/amenorrhea in women with polycystic ovary syndrome: a randomized controlled trial. *Am J Physiol Endocrinol Metab* 2011;300(1):E37-45. doi: 10.1152/ajpendo.00495.2010

[6] Johansson J, Redman L, Veldhuis PP, et al. Acupuncture for ovulation induction in polycystic ovary syndrome: a randomized controlled trial. *Am J Physiol Endocrinol Metab* 2013;304(9):E934-43. doi: 10.1152/ajpendo.00039.2013

[7] Benrick A, Kokosar M, Hu M, et al. Autonomic nervous system activation mediates the increase in whole-body glucose uptake in response to electroacupuncture. *FASEB J* 2017;31(8):3288-97. doi: 10.1096/fj.201601381R

[8] Wu XK, Stener-Victorin E, Kuang HY, et al. Effect of Acupuncture and Clomiphene in Chinese Women With Polycystic Ovary Syndrome: A Randomized Clinical Trial. *JAMA* 2017;317(24):2502-14. doi: 10.1001/jama.2017.7217

[9] Pastore LM, Williams CD, Jenkins J, et al. True and sham acupuncture produced similar frequency of ovulation and improved LH to FSH ratios in women with polycystic ovary syndrome. *J Clin Endocrinol Metab.* 2011;96(10):3143-3150. doi: 10.1210/jc.2011-1126.

[10] Cherkin DC, Sherman KJ, Avins AL, et al. A randomized trial comparing acupuncture, simulated acupuncture, and usual care for chronic low back pain. *Arch Intern Med* 2009;169(9):858-66. doi: 10.1001/archinternmed.2009.65

[11] Ko S J, Kuo B, Kim S K, et al. Individualized Acupuncture for Symptom Relief
in Functional Dyspepsia: A Randomized Controlled Trial. *J Altern Complement Med* 2016; 22(12): 997-1006. doi: 10.1089/acm.2016.0208

[12] Macklin EA, Wayne PM, Kalish LA, et al. Stop Hypertension with the Acupuncture Research Program (SHARP): results of a randomized, controlled clinical trial. *Hypertension* 2006;48(5):838-45. doi: 10.1161/01.HYP.0000241090.28070.4c

[13] Zheng YH, Wang XH, Lai MH, et al. Effectiveness of abdominal acupuncture for patients with obesity-type polycystic ovary syndrome: a randomized controlled trial. *J Altern Complement Med*, 2013, 19(9):740-745. doi: 10.1089/acm.2012.0429

[14] Wu L, Chen X, Liu Y, et al. Role of acupuncture in the treatment of insulin resistance: A systematic review and meta-analysis. *Complement Ther Clin Pract*. 2019; 37: 11-22. doi: 10.1016/j.ctcp.2019.08.002.

[15] Kim TH, Kang JW, Sul JU, et al. Acupuncture for symptom management in hemodialysis patients: a prospective, observational pilot study. *J Altern Complement Med* 2011;17(8) :741-8. doi: 10.1089/acm.2010.0206

[16] Kreindler G, Attias S, Kreindler A, et al. Treating postlaparoscopic surgery shoulder pain with acupuncture. *Evid Based Complement Alternat Med* 2014:1-7. doi: 10.1155/2014/120486

[17] Chen HY, Liu NY. Analgesic Effect of Sinew Acupuncture for Patients with Soft-Tissue Injuries: A Pilot Trial. *Chin J Integr Med* 2019;25(8):613-616. doi: 10.1007/s11655-019-3061-3

[18] Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010;340:c869. doi: 10.1136/bmj.c869

[19] MacPherson H, Altman DG, Hammerschlag R, et al. Revised STAndards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the
CONSORT statement. *PLoS Med* 2010;7(6):e1000261. doi: 10.1371/journal.pmed.1000261

[20] Chan A W, Tetzlaff J M, Altman D G, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Annals of Internal Medicine*, 2013, 158(3):200-207. doi: 10.7326/0003-4819-158-3-201302050-00583

[21] Zhao X, Ni R, Li L, et al. Defining hirsutism in Chinese women: a cross-sectional study. *Fertil Steril* 2011;96(3):792-6. doi: 0.1016/j.fertnstert.2011.06.040

[22] Ni R M, Mo Y, Chen X, et al. Low prevalence of the metabolic syndrome but high occurrence of various metabolic disorders in Chinese women with polycystic ovary syndrome. *Eur J Endocrinol* 2009, 161(3):411-8. doi: 10.1530/EJE-09-0298.

[23] NBalen AH, Laven JS, Tan SL, et al. Ultrasound assessment of the polycystic ovary: international consensus definitions. *Hum Reprod Update* 2003;9(6):505-14. doi: 10.1093/humupd/dmg044

[24] Cooper TG, Noonan E, von Eckardstein S, et al. World Health Organization Reference Values for Human Semen Characteristics. *Human Reproduction Update*. 2010; 16 (3): 231-45. doi: 10.1093/humupd/dmp048

[25] Jin C, Pang R, Xu L, et al. Clinical rules for acupoint selection and prescription composition in treatment of polycystic ovary syndrome with acupuncture. *Zhongguo Zhen Jiu* 2015;35(6):625-30.

[26] Wu X K, Wang Y Y, Liu J P, et al. Randomized controlled trial of letrozole, berberine, or a combination for infertility in the polycystic ovary syndrome. *Fertil Steril*, 2016; 106 (3): 757-765. doi: 10.1016/j.fertnstert.2016.05.022.

[27] Chang J, Li X J. Literature review on distribution features of TCM syndrome of polycystic ovarian syndrome. *Chinese Journal of Human Sexuality*. 2014(03):64-67. doi: 10.3969/j.issn.1672-1993.2014.03.022.
| Point                        | Stimulation | Location                                      |
|------------------------------|-------------|-----------------------------------------------|
| **Spleen-yang and kidney-yang deficiency** |
| Sanyinjiao (bilateral) (SP6) | EA, (+)     | 3 cun proximal to the medial malleol         |
| Tianshu (bilateral) (ST25)   | A           | 2 cun lateral to the midline                 |
| Zigong (bilateral) (EX-CA1)  | A           | 1 cun cranial to the pubic bone and the midline |
| Guanyuan (CV4)               | A           | 3 cun caudal to the umbilicus                |
| Zhongwan (CV12)              | A           | 4 cun superior to the umbilicus              |
| Qihai (CV6)                  | A           | 1.5 cun caudal to the umbilicus              |
| Fenglong (bilateral) (ST40)  | Deqi 4 times, (-) | 8 cun superior to lateral malleol        |
| Yinlingquan (bilateral) (SP9)| EA, (-)     | Below medial tibia chondyle                 |
| Zusanli (bilateral) (ST36)   | Deqi 4 times, (+) | On the anterior lateral side of Dubi (ST35), one finger width from the anterior crest of the tibia |
| **Liver-yin and kidney-yin deficiency** |
| Sanyinjiao (bilateral) (SP6) | EA, (+)     | 3 cun proximal to the medial malleol         |
| Tianshu (bilateral) (ST25)   | A           | 3 cun caudal to the umbilicus                |
Zigong (bilateral) (EX-CA1) & A & 1 cun cranial to the pubic bone and 3 cun lateral to the midline \\
Guanyuan (CV4) & A & 3 cun caudal to the umbilicus \\
Zhongwan (CV12) & A & 4 cun superior to the umbilicus \\
Qihai (CV6) & A & 1.5 cun caudal to the umbilicus \\
Fenglong (bilateral) (ST40) & Deqi 4 times, (-) & 8 cun superior to lateral malleolus \\
Yinlingquan (bilateral) (SP9) & EA, (-) & Below medial tibia chondyle \\
Taixi (bilateral) (K13) & Deqi 4 times, (+) & Behind the medial malleolus \\
Taichong (bilateral) (LR3) & Deqi 4 times, (-) & Between metatarsal I and II, justl \\

+/-, signifies that these points have been rotated bi-directionally to tonifying (+) or sedating (-).

A, acupuncture; CV, conception vessel; EA, electroacupuncture; EX-CA, extra point of chest and abdomen; GV, governor vessel; K, kidney; L, lumbar vertebra; LI, large intestine; LR, liver; M., musculi; Mm., musculus; S, sacral vertebra; ST, stomach; SP, spleen; Th, thoracic vertebra.

Table 2 Fixed acupuncture protocol

| Point             | Stimulation | Location                        |
|-------------------|-------------|---------------------------------|
| Zhongji (CV3)     | EA          | 4 cun caudal to the umbilicus   |
| Qihai (CV6)       | EA          | 1.5 cun caudal to the umbilicus |
| Point                  | Technique    | Description                                                                 |
|-----------------------|--------------|-----------------------------------------------------------------------------|
| Guilai (bilateral) (ST29) | EA          | 1 cun cranial to the pubic bone and 2 cun lateral to the midline             |
|                      |              | M. rectus abdominis                                                        |
| Sanyinjiao (bilateral) (SP6) | EA          | 3 cun proximal to the medial malleolus                                     |
|                      |              | Mm flexor digitorum longus, tibialis posterior                              |
| Yinlingquan (bilateral) (SP9) | EA          | Below medial tibia condyle                                                 |
|                      |              | M. gastrocnemius                                                           |
| Hegu (bilateral) (LI4) | DeQi 4 times | On the highest point at the musculi interosseus dorsalis                    |
|                      |              | Mm flexor digitorum longus, tibialis posterior                              |
| Baihui (GV20)         | DeQi 4 times | On the top of head                                                          |
|                       |              | Apc                                                                        |
| **Set 2**             |              |                                                                            |
| Tianshu (bilateral) (ST25) | EA          | 2 cun lateral to the midline at the level of the umbilicus                 |
| Guilai (bilateral) (ST29) | EA          | 1 cun cranial to the pubic bone and 2 cun lateral to the midline           |
| Zhongji (CV3)         | A            | 4 cun caudal to the umbilicus                                              |
| Qihai (CV6)           | A            | 1.5 cun caudal to the umbilicus                                             |
| Sanyinjiao (bilateral) (SP6) | EA          | 3 cun proximal to the medial malleolus                                    |
| Taichong (bilateral) (LR3) | EA          | Between metatarsal I and II, just distal to the caput                      |
| Neiguan (bilateral) (PC6) | DeQi 4 times | 2 cun proximal to the processus styloideus radii, between the tendons of the palmaris longus and the flexor carpi radialis |
| Baihui (GV20)         | DeQi 4 times | On the top of head                                                          |

The two sets will be alternated for every other treatment.

A, acupuncture; C, cervical vertebra; CV, conception vessel; EA, electroacupuncture; GV, governor vessel; L, lumbar vertebra; LI, large intestine; LR, liver; M., musculi; Mm., musculus; PC, pericardium; S, sacral vertebra; SP, spleen; ST, stomach; Th, thoracic vertebra

Table 3. Overview of the study visits
| Screening Visit | Baseline Visit | Treatments |  
|-----------------|----------------|------------|
|                 |                | Personalized Acupuncture | Fixed Acupuncture |
| Sign Consent    | x              | x          | x          |
| History         | x              | x          | x          |
| Urine pregnancy test | x        | x          | x          |
| Physical Exam   | x              | x          | x          |
| Transvaginal ultrasound | x       | x          | x          |
| Semen Analysis  | x              | x          | x          |
| Hysterosalpingogram | x       | x          | x          |
| Cervical Pap smear or TCT | x    | x          | x          |
| Preconception counselling | x   | x          | x          |
| Fasting blood for study eligibility Lads | x | x | x |
| Blood samples collection | x | x | x |
| Serum progesterone assay | x | x | x |
| Serum HCG assay | x              | x          | x          |
| Questionnaires  | x              | x          | x          |
| Acupuncture Visits (three times weekly) | x | x | x |
| Assess adverse events and concomitant medications | x | x | x |
| Pregnancy and neonatal records | x | x | x |

Physical examination: weight, height, waist circumference, hip circumference, FG/acne.
Fasting blood for study eligibility Lads: FSH, LH, SHBG, T, free testosterone, E2, PRL, FGLU, FINS, C-peptide, HbA1c, cl
Transvaginal ultrasound: endometrial thickness, ovarian volume, antral follicle count, and size of ovarian cysts or developing follicles.
Preconception counselling: TORCH and HIV screening.
Blood samples collection: serum for the central core laboratory.
Abbreviation: CBC, complete blood count; E2, estradiol; FG, Ferriman-Gallwey; FGLU, fasting blood glucose; FINS, fast
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LH, luteinising hormone; PRL, prolactin; SHBG, sex hormone-binding globulin; T, total testosterone; TCT, thinprep cytologic test; TORCH, Toxoplasmosis, Rubella, Cytomegalovirus, and Herpes virus.

Figures

Figure 1

Moxibustion in personalized acupuncture group. (a) 1.5 moxa sticks for a treatment
Figure 2

The study flow chart main document. PCOS, polycystic ovary syndrome.

Supplementary Files

This is a list of supplementary files associated with the primary manuscript. Click to download.

Supplementary file 2 - Patient information and consent.docx
SPIRIT checklist 20190829.doc
Supplementary file 1 - SPIRIT checklist.doc
